Keeping you up to date on recent developments in orthopedics, including: X-rays confirm promise of new luminescent markers; Pillar of support: Breakthrough discovery could speed up bone implant recovery; New biosealant can stabilize cartilage, promote healing after injury.
A French study has demonstrated that the novel agonist anti-human ChemR23 monoclonal antibody (MAb) designated OSE-230 accelerated recovery from acute inflammation and triggered resolution of chronic inflammation in mice chronic colitis models, preventing fibrosis and reducing tumor development.
Keeping you up to date on recent developments in oncology, including: NIH drug screening protocol identifies treatment for SCLC; Explanation for DR5 antibody problem surfaces; Location, location, location in avoidance of esophagitis.
A Korean study led by Seoul National University scientists is the first to demonstrate that the human intestinal mucin-degrading bacterium, Akkermansia muciniphila, secretes a glucagon-like peptide-1 (GLP-1)-inducing protein, which significantly improved glucose homeostasis and ameliorated metabolic disease in mice.
Keeping you up to date on recent developments in cardiology, including: Rheumatic aortic stenosis responds well to TAVR vs. SAVR; Cardiac MR may improve correct diagnosis of left ventricular non-compaction; Better management needed for infarct patients with mechanical complications.
Cachexia, Teresa Zimmers told the audience at the Annual Meeting of the American Association for Cancer Research (AACR), is "woefully understudied for the outsized impact it has on cancer patients." The condition, which is currently defined as weight loss and muscle wasting, is the direct cause of death in an estimated 25% to 30% of cancer patients. But it is the main subject of only 0.1% of research papers and 0.2% of clinical trials.
Keeping you up to date on recent developments in neurology, including: Blood test for depression, bipolar disorder developed; Specialized hydrogel helps repair circuitry in severe TBI; Using AI to diagnose neurological diseases based on motor impairment.
A splicing defect in the survival of motor neuron gene (SMN) leads to a deficiency of protein function that results in spinal muscular atrophy. It is the second most common autosomal recessive disease, occurring with a prevalence of 1 to as little as 6,000 births.
LONDON – The largest study to date, involving 236,379 confirmed cases, shows that 1 in 3 survivors of COVID-19 was diagnosed with a neurological or psychiatric condition within six months of contracting the infection. For 13% of those patients, it was their first such diagnosis.